OBJECTIVE: Hydroxyurea has proven laboratory and clinical therapeutic benefits for sickle cell anemia and other diseases, yet many questions remain about its in vivo pharmacokinetic and pharmacodynamic profiles. Previous reports suggest that hydroxyurea passively diffuses across cells, but its observed rapid absorption and distribution are more consistent with facilitated or active transport. We investigated the potential role of solute carrier (SLC) transporters in cellular uptake and accumulation of hydroxyurea. MATERIALS AND METHODS: Passive diffusion of hydroxyurea across cell membranes was determined using the parallel artificial membrane permeability assay. SLC transporter screens were conducted using in vitro intracellular drug accumulation and transcellular transport assays in cell lines and oocytes overexpressing SLC transporters. Gene expression of SLC transporters was measured by real-time polymerase chain reaction in human tissues and cell lines. RESULTS: Hydroxyurea had minimal diffusion across a lipid bilayer but was a substrate for five different SLC transporters belonging to the organic cation/carnitine transporters and organic anion transporting polypeptides (OATP) families of transporters and urea transporters A and B. Further characterization of hydroxyurea transport revealed that cellular uptake by OATP1B3 is time- and temperature-dependent and inhibited by known substrates of OATP1B3. Urea transporters A and B are expressed differentially in human tissues and erythroid cells, and transport hydroxyurea bidirectionally via facilitated diffusion. CONCLUSIONS: These studies provide new insight into drug transport proteins that may be involved in the in vivo absorption, cellular distribution, and elimination of hydroxyurea. Elucidation of hydroxyurea transcellular movement should improve our understanding of its pharmacokinetics and pharmacodynamics, and may help explain some of the interpatient drug variability observed in patients with sickle cell anemia.
OBJECTIVE:Hydroxyurea has proven laboratory and clinical therapeutic benefits for sickle cell anemia and other diseases, yet many questions remain about its in vivo pharmacokinetic and pharmacodynamic profiles. Previous reports suggest that hydroxyurea passively diffuses across cells, but its observed rapid absorption and distribution are more consistent with facilitated or active transport. We investigated the potential role of solute carrier (SLC) transporters in cellular uptake and accumulation of hydroxyurea. MATERIALS AND METHODS: Passive diffusion of hydroxyurea across cell membranes was determined using the parallel artificial membrane permeability assay. SLC transporter screens were conducted using in vitro intracellular drug accumulation and transcellular transport assays in cell lines and oocytes overexpressing SLC transporters. Gene expression of SLC transporters was measured by real-time polymerase chain reaction in human tissues and cell lines. RESULTS:Hydroxyurea had minimal diffusion across a lipid bilayer but was a substrate for five different SLC transporters belonging to the organic cation/carnitine transporters and organic anion transporting polypeptides (OATP) families of transporters and urea transporters A and B. Further characterization of hydroxyurea transport revealed that cellular uptake by OATP1B3 is time- and temperature-dependent and inhibited by known substrates of OATP1B3. Urea transporters A and B are expressed differentially in human tissues and erythroid cells, and transport hydroxyurea bidirectionally via facilitated diffusion. CONCLUSIONS: These studies provide new insight into drug transport proteins that may be involved in the in vivo absorption, cellular distribution, and elimination of hydroxyurea. Elucidation of hydroxyurea transcellular movement should improve our understanding of its pharmacokinetics and pharmacodynamics, and may help explain some of the interpatient drug variability observed in patients with sickle cell anemia.
Authors: Mariane de Montalembert; Dora Bachir; Anne Hulin; Linda Gimeno; Agnès Mogenet; Jean Louis Bresson; Isabelle Macquin-Mavier; Françoise Roudot-Thoraval; Alain Astier; Frédéric Galactéros Journal: Haematologica Date: 2006-12 Impact factor: 9.941
Authors: T R Kinney; R W Helms; E E O'Branski; K Ohene-Frempong; W Wang; C Daeschner; E Vichinsky; R Redding-Lallinger; B Gee; O S Platt; R E Ware Journal: Blood Date: 1999-09-01 Impact factor: 22.113
Authors: Vladan P Cokic; Reginald D Smith; Bojana B Beleslin-Cokic; Joyce M Njoroge; Jeffery L Miller; Mark T Gladwin; Alan N Schechter Journal: J Clin Invest Date: 2003-01 Impact factor: 14.808
Authors: Russell E Ware; Jenny M Despotovic; Nicole A Mortier; Jonathan M Flanagan; Jin He; Matthew P Smeltzer; Amy C Kimble; Banu Aygun; Song Wu; Thad Howard; Alex Sparreboom Journal: Blood Date: 2011-08-29 Impact factor: 22.113
Authors: Aisha L Walker; Cynthia S Lancaster; David Finkelstein; Russell E Ware; Alex Sparreboom Journal: Am J Physiol Cell Physiol Date: 2013-08-28 Impact factor: 4.249
Authors: David I Fraser; Kyle T Liu; Bryan J Reid; Emily Hawkins; Andrew Sevier; Michelle Pyle; Jacob W Robinson; Pierre H R Ouellette; James S Ballantyne Journal: PLoS One Date: 2015-11-24 Impact factor: 3.240
Authors: Madelyn C Huang; Katie J Turner; Molly Vallant; Veronica G Robinson; Yi Lu; Catherine J Price; Timothy R Fennell; Melanie A Silinski; Suramya Waidyanatha; Kristen R Ryan; Sherry R Black; Reshan A Fernando; Barry S McIntyre Journal: J Appl Toxicol Date: 2020-11-25 Impact factor: 3.628